PODD - Insulet Corporation
90.10 0.00 (0.00%)
After hours: 4:00PM EDT
| Previous Close | 92.41 |
| Open | 92.16 |
| Bid | 85.00 x 1100 |
| Ask | 90.48 x 1300 |
| Day's Range | 89.42 - 92.50 |
| 52 Week Range | 56.62 - 108.91 |
| Volume | 414,370 |
| Avg. Volume | 657,210 |
| Market Cap | 5.316B |
| Beta (3Y Monthly) | 1.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.30 |
| Earnings Date | Nov 1, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 106.07 |
Market Realist•9 hours agoWhat Can We Expect from Tandem’s Bottom Line in Third Quarter?
Tandem Diabetes Care (TNDM) is expected to incur a net loss of $18.22 million in the third quarter of 2018. Its net loss was $16.03 million in the year-ago period, which translates into a net loss per share of $0.33 for the third quarter of fiscal 2018 as compared with a net loss per share of $3.09 for the third quarter of fiscal 2017. On October 12, Tandem announced that its t:slim X2 insulin pump received approval in Canada and is the only continuous glucose monitoring (or CGM) integrated insulin pump approved in the country.
Market Realist•7 days agoCould JNJ’s Medical Device Business Report Strong Growth in Q3?
Johnson & Johnson’s (JNJ) Medical Device business has posted steadily improving performance in recent quarters. Since then, Johnson & Johnson has efficiently implemented a restructuring plan for its Medical Device business, which resulted in significant growth in the segment’s performance. In the second quarter, Johnson & Johnson’s Medical Device business reported sales of ~$7.0 billion, which contributed 33.5% to the company’s total sales of $20.8 billion.
Markit•7 days agoSee what the IHS Markit Score report has to say about Insulet Corp.
Insulet Corp NASDAQ/NGS:PODD
- Zacks•14 days ago
Europe Okays Use of Insulet's (PODD) Omnipod With Fiasp
Fiasp's operative efficiency coupled with Insulet's (PODD) Omnipod System will provide a new option for both patients and prescribers to support their diabetes management requirements.
- Business Wire•17 days ago
Omnipod® Insulin Management System Now Available for Use in Europe with Fiasp® Fast-Acting Insulin
Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that Novo Nordisk’s Fiasp® (Fast-Acting Insulin Aspart) has been tested and found safe for use in Insulet’s Omnipod System in Europe. Fiasp® is a new-generation, ultra fast-acting insulin developed by Novo Nordisk that enters the bloodstream two times faster, compared to NovoRapid®, so it more closely matches a healthy body’s insulin response to a meal, thereby improving glycemic control.
- Motley Fool•21 days ago
Investing in Diabetes Stocks: A Beginner's Guide
Want to put money to work in this $825 billion market? Here's what you need to know.
Market Realist•22 days agoWhy TNDM’s Stock Price Rose 7.4% on September 25
On September 25, Tandem Diabetes Care’s (TNDM) stock price closed at $47.84, which represents ~7.43% growth from the close of $44.53 on September 24. On September 20, Tandem Diabetes Care’s stock price grew 8.09% to 43.18 from the close of $39.95 on September 19.
- Business Wire•25 days ago
Insulet to Announce Third Quarter 2018 Financial Results on November 1, 2018
Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced plans to release its financial results for the third quarter of 2018 on November 1, 2018 after the close of the financial markets. The link to the live call will be available on the Investor Relations section of the Company's website at http://investors.insulet.com, “Events and Presentations”, and will be archived for future replay. You may also access the live call by dialing (844) 831-3022 for domestic callers or (315) 625-6887 for international callers, passcode is 6887887.
Markit•28 days agoSee what the IHS Markit Score report has to say about Insulet Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Zacks•29 days ago
Insulet Advances on Omnipod Reimbursement Update, Runs Risks
Insulet (PODD) commences 2018 with favorable reimbursement updates. The company attains several landmarks regarding Omnipod's market reach.
Markit•last monthSee what the IHS Markit Score report has to say about Insulet Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Benzinga•last month
The Daily Biotech Pulse: Advaxis Posts Narrower Loss, Endocyte Announces $175M Offering, Leadership Transition At Insulet
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Stocks that hit 52-week highs Sept. 7.) Amgen, Inc. (NASDAQ: AMGN )/p BioSpecifics Technologies ...
- Business Wire•last month
Insulet Announces Shacey Petrovic, President and COO, Promoted to CEO, Effective January 1, 2019; Patrick Sullivan Will Retire as Chairman and CEO at the End of 2018
Insulet Corporation (PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that Shacey Petrovic, President and Chief Operating Officer, will succeed Patrick Sullivan as Insulet’s Chief Executive Officer, effective January 1, 2019.
Markit•last monthSee what the IHS Markit Score report has to say about Insulet Corp.
Insulet Corp NASDAQ/NGS:PODD
- Motley Fool•last month
3 Growth Stocks for Forward-Looking Investors
If you're a long-term investor, these growth stocks are for you.
Markit•last monthSee what the IHS Markit Score report has to say about Insulet Corp.
Insulet Corp NASDAQ/NGS:PODD
Markit•last monthSee what the IHS Markit Score report has to say about Insulet Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
- Business Wire•2 months ago
Insulet to Present at Upcoming Investor Conferences
Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management wil
- Zacks•2 months ago
Zacks.com featured highlights include: Entercom, Insulet, ESCO and Tristate
Zacks.com featured highlights include: Entercom, Insulet, ESCO and Tristate
- Zacks•2 months ago
4 Top Stocks With the Power of Earnings Acceleration
Studies show that a majority of successful stocks see acceleration in earnings before a positive stock price movement.
- Business Wire•2 months ago
Insulet to Showcase Its Omnipod DASH™ Insulin Management System at the American Association of Diabetes Educators Annual Conference
Insulet Corporation , the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System , today announced it will showcase its recently FDA cleared Omnipod DASH™ Insulin Management System , during the American Association of Diabetes Educators meeting at the Baltimore Convention Center in Baltimore, Maryland on August 17-20, 2018.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of PODD earnings conference call or presentation 2-Aug-18 8:30pm GMT
Q2 2018 Insulet Corp Earnings Call
Markit•2 months agoSee what the IHS Markit Score report has to say about Insulet Corp.
Insulet Corp NASDAQ/NGS:PODD
- Zacks•2 months ago
Insulet (PODD) Q2 Loss Narrower Than Expected, Revenues Lag
We are encouraged by the year-over-year improvement in Insulet's (PODD) results on solid uptake of Omnipod system in the United States in Q2.
